Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

被引：0
|
作者：
Harrison, Claire N. [1 ]
Vannucchi, Alessandro M. [2 ]
Kiladjian, Jean-Jacques [3 ,4 ]
Al-Ali, Haifa Kathrin [5 ]
Gisslinger, Heinz [6 ]
Knoops, Laurent [7 ,8 ]
Cervantes, Francisco [9 ]
Jones, Mark M. [10 ]
Sun, Kang [10 ]
Descamps, Laurence [11 ]
Stalbovskaya, Viktoriya [12 ]
Gopalakrishna, Prashanth [12 ]
Barbui, Tiziano [13 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[2] Univ Florence, Florence, Italy
[3] Hop St Louis, Paris, France
[4] Univ Paris Diderot, Paris, France
[5] Univ Leipzig, D-04109 Leipzig, Germany
[6] Med Univ Vienna, Vienna, Austria
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
[8] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium
[9] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain
[10] Incyte Corp, Wilmington, DE USA
[11] Novartis Pharma SAS, Rueil Malmaison, France
[12] Novartis Pharma AG, Basel, Switzerland
[13] Hosp Papa Giovanni XXIII & Res Fdn, Bergamo, Italy
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)
    Cervantes, Francisco
    Kiladjian, Jean-Jacques
    Niederwieser, Dietger
    Sirulnik, Andres
    Stalbovskaya, Viktoriya
    McQuity, Mari
    Hunter, Deborah S.
    Levy, Richard S.
    Passamonti, Francesco
    Barbui, Tiziano
    Barosi, Giovanni
    Gisslinger, Heinz
    Vannucchi, Alessandro M.
    Knoops, Laurent
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [2] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2016, 30 : 1701 - 1707
  • [3] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2016, 30 (08) : 1701 - 1707
  • [4] Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    Cervantes, Francisco
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa Kathrin
    Sirulnik, Andres
    Stalbovskaya, Viktoriya
    McQuitty, Mari
    Hunter, Deborah S.
    Levy, Richard S.
    Passamonti, Francesco
    Barbui, Tiziano
    Barosi, Giovanni
    Harrison, Claire N.
    Knoops, Laurent
    Gisslinger, Heinz
    BLOOD, 2013, 122 (25) : 4047 - 4053
  • [5] LONG-TERM OUTCOMES FROM A PHASE 3 STUDY COMPARING RUXOLITINIB WITH BEST AVAILABLE THERAPY ( BAT) FOR THE TREATMENT OF MYELOFIBROSIS (MF): A 3-YEAR UPDATE OF COMFORT-II
    Vannucchi, A.
    Cervantes, F.
    Niederwieser, D.
    Sirulnik, A.
    Stalbovskaya, V.
    McQuitty, M.
    Levy, R.
    Passamonti, F.
    Barbui, T.
    Gisslinger, H.
    Knoops, L.
    Harrison, C.
    Barosi, G.
    Kiladjian, J.
    HAEMATOLOGICA, 2013, 98 : 456 - 457
  • [6] Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2017, 31 : 775 - 775
  • [7] RESULTS FROM A 3.5-YEAR UPDATE OF COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB (RUX) WITH BEST AVAILABLE THERAPY (BAT) FOR THE TREATMENT OF MYELOFIBROSIS
    Harrison, C.
    Niederwieser, D.
    Vannucchi, A.
    Kiladjian, J. J.
    Barbui, T.
    Gisslinger, H.
    Passamonti, F.
    Cervantes, F.
    Al-Ali, H. K.
    Cilloni, D.
    Zachee, P.
    Descamps, L.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Knoops, L.
    Barosi, G.
    HAEMATOLOGICA, 2014, 99 : 126 - 127
  • [8] Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis (vol 122, pg 4047, 2013)
    Cervantes, F.
    Vannucchi, A. M.
    Kiladjian, J-J
    BLOOD, 2016, 128 (25) : 3013 - 3013
  • [9] Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (vol 30, pg 1701, 2016)
    Harrison, C. N.
    Vannucchi, A. M.
    Kiladjian, J-J
    Al-Ali, H. K.
    Gisslinger, H.
    Knoops, L.
    Cervantes, F.
    Jones, M. M.
    Sun, K.
    McQuitty, M.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Barbui, T.
    LEUKEMIA, 2017, 31 (03) : 775 - 775
  • [10] The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
    McMullin M.F.
    Harrison C.N.
    Niederwieser D.
    Demuynck H.
    Jäkel N.
    Gopalakrishna P.
    McQuitty M.
    Stalbovskaya V.
    Recher C.
    Theunissen K.
    Gisslinger H.
    Kiladjian J.-J.
    Al-Ali H.-K.
    Experimental Hematology & Oncology, 4 (1)
12345